Use of phytocanabinoids in animal models of Parkinson's disease: Systematic review.

Autor: Alves ADF; Department of Veterinary Medicine, Federal Rural University of Pernambuco, Brazil. Electronic address: amandadedeusfa@gmail.com., Dias FCR; Department of Veterinary Medicine, Federal Rural University of Pernambuco, Brazil; Cellular Interactions Laboratory, Institute of Biological and Natural Sciences, Federal University of Triângulo Mineiro, Uberaba, MG, Brazil., Cadena PG; Department of Morphology and Animal Physiology, Federal Rural University of Pernambuco, Brazil., Silva-Jr VA; Department of Veterinary Medicine, Federal Rural University of Pernambuco, Brazil.
Jazyk: angličtina
Zdroj: Neurotoxicology [Neurotoxicology] 2024 Aug 23; Vol. 105, pp. 34-44. Date of Electronic Publication: 2024 Aug 23.
DOI: 10.1016/j.neuro.2024.08.002
Abstrakt: This systematic review was carried out with the aim of evaluating the use of medicinal Cannabis for the treatment of Parkinson's disease in experimental models. Furthermore, we sought to understand the main intracellular mechanisms capable of promoting the effects of phytocannabinoids on motor disorders, neurodegeneration, neuroinflammation and oxidative stress. The experimental models were developed in mice, rats and marmosets. There was a predominance of using only males in relation to females; in three studies, the authors evaluated treatments in males and females. Drugs were used as inducers of Parkinson's disease: 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), lipopolysaccharide (LPS), and rotenone. Substances capable of promoting catalepsy in animals were also used: haloperidol, L-nitro-N-arginine (L-NOARG), WIN55,212-2, and reserpine. The inducing agent was injected stereotaxically or intraperitoneally. The most commonly used treatments were cannabidiol (CBD), Delta-9-tetrahydrocannabinol (Δ-9 THC) and Delta-9-tetrahydrocannabivarin (Δ-9 THCV), administered intraperitoneally, orally, subcutaneously and intramuscularly. The use of phytocannabinoids improved locomotor activity and involuntary movement and reduced catalepsy. There was an improvement in the evaluation of dopaminergic neurons, while in relation to dopamine content, the treatment had no effect. Inflammation, microglial/astrocyte activation and oxidative stress were reduced after treatment with phytocannabinoids, the same was observed in the results of tests for allodynia and hyperalgesia.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: